MTDA

MTDA, or MPDA, also known as 3-methoxy-4,5-trimethylenedioxyamphetamine or as 5-methoxy-TDA, is a chemical compound of the phenethylamine and amphetamine families related to the MDxx compounds like MDMA and the EDxx compounds like EDMA.^[1][2][3] It is the 5-methoxy derivative of 3,4-trimethylenedioxyamphetamine (TDA) and the analogue of MMDA (5-methoxy-MDA) and MEDA (5-methoxy-EDA) in which the 3,4-alkylenedioxy ring is a further-expanded 3,4-trimethylenedioxy ring.^[1][2][3] It was synthesized, tested, and described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).^[1][2][3] He tested it at doses of up to 8 mg orally and observed no activity.^[1][2][3] He did not expect any activity and did not test higher doses before abandoning it, due to it being "not an interesting compound".^[1][2][3] MTDA was first described in the scientific literature by Shulgin by 1964.^[4][5]

MTDA

Clinical data
Other names	MPDA; 3-Methoxy-4,5-trimethylenedioxyamphetamine; 5-Methoxy-3,4-trimethylenedioxyamphetamine; 5-Methoxy-TDA; 5-MeO-TDA
ATC code	None
Identifiers
IUPAC name 1-(6-methoxy-3,4-dihydro-2H-1,5-benzodioxepin-8-yl)propan-2-amine
PubChem CID	170864921
Chemical and physical data
Formula	C13H19NO3
Molar mass	237.299 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(CC1=CC2=C(C(=C1)OC)OCCCO2)N
InChI InChI=1S/C13H19NO3/c1-9(14)6-10-7-11(15-2)13-12(8-10)16-4-3-5-17-13/h7-9H,3-6,14H2,1-2H3 Key:XCXNZPQOBJFUIH-UHFFFAOYSA-N

See also

• Substituted phenethylamine
• Substituted ethylenedioxyphenethylamine
• MEDA (5-methoxy-EDA)